Royal Agrifirm Group has reached an agreement to acquire Hamlet Protein, with the transaction expected to close in the coming weeks. The move is set to enhance the combined capabilities in early-life animal nutrition by aligning Hamlet Protein’s technology with Agrifirm’s global network and nutritional expertise. Both parties highlight growth, innovation, and long-term strategic value as key drivers of the deal.

Royal Agrifirm Group, headquartered in the Netherlands, has entered into an agreement with Hamlet Protein’s owners to bring the company into its portfolio. The acquisition is aimed at strengthening offerings in early-life nutrition by combining technical capabilities and international reach. Upon completion, Hamlet Protein will continue operating under its own brand as part of the group.

CEO Piet Hilarides said the acquisition aligns with the company’s mission, explaining that “Hamlet Protein’s proven technology strengthens us to help customers achieve optimal early-life results, which fits directly with our purpose of contributing to a responsible food chain for future generations.”

From the ownership side, Altor expressed confidence in the transition. Søren Johansen, Partner at Altor, stated that “Agrifirm’s focus on specialty nutrition, and its international presence create an excellent platform for Hamlet Protein to further scale its technology and impact.”

Hamlet Protein CEO Erik Visser emphasized future opportunities, noting that “joining Royal Agrifirm Group allows us to accelerate our development, expand our global reach and continue delivering high-digestibility solutions that support young animal health and performance. This step creates new opportunities for both our customers and our employees.”

Hamlet Protein, known for its specialized young animal nutrition solutions, will retain its brand identity while leveraging Agrifirm’s broader infrastructure to expand innovation, market access, and technical development across global markets.